Mankind Pharma to buy 70% in Belgium biotech ACTx for about EUR 48 million

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹2347.60

prior close

₹2349.90

announcement price

After-mkt

timing

Nifty Midcap 150market-0.1%-3.0% vs market

Pharmaceuticals peers, median of 173sector+0.1%-3.2% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Midcap 150 and 3.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.9

15m

-0.8

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1-0.1-3.0+0.1-3.2

Next day

-4.0-1.2-2.8-1.2-2.8

-2.6-2.6-0.1-3.0+0.3

-3.1-3.3+0.3-3.9+0.8

-5.8-5.3-0.4-5.0-0.7

-1.5-4.3+2.8-3.9+2.4

+6.1-3.2+9.2-0.9+7.0

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved additional investment of up to EUR 45 million in wholly owned Mankind Pharma Netherlands, raising total investment limit there to EUR 50 million. Mankind Netherlands will invest EUR 48 million to acquire 70 percent stake in Belgium-based Armed Cell Therapeutics (ACTx), a biotech developing next-generation CAR-T cell therapies for cancers including non-Hodgkin lymphoma and small cell lung cancer. Deal is cash funded. Funds part of Mankind's long-term plan to build a global innovation-led pharma business and bring advanced therapies to India and worldwide.

Likely market impact

Entry into cutting-edge CAR-T cancer therapy through a majority buy supports long-term global growth ambitions. Execution and regulatory risks remain.